

1. Please click here ^[1] to download the group picture of your seminar.

2. Presentations:

1. Therapeutic drug monitoring for all drugs and for all patients?^[2]

Dr Ute Blassmann^[3], Heidelberg University Hospital, Germany

2. Do we need therapeutic drug monitoring for beta lactams or can we just use prolonged infusions? ^[4]

Dr Ute Blassmann^[3], Heidelberg University Hospital, Germany

3. The impact of PK/PD for clinical decisions ^[5]

Dr Anouk Muller^[6], HaaglandenMC, The Hague and ErasmusMC, Rotterdam

4. MIC directed therapy: why, when and what are the pitfalls? ^[7]

Dr Anouk Muller^[6], HaaglandenMC, The Hague and ErasmusMC, Rotterdam

5. Interactive Part – clinical cases – PK/PD ^[8]

Prof Dr Isabel Spriet^[9], UZ Leuven, Belgium

Dr Peter Declercq^[10], University Hospitals Leuven, Belgium

6. Implementation of check of medication appropriateness: what can the computer do for ABS? ^[11]

Prof Dr Isabel Spriet ^[9], UZ Leuven, Belgium

7. Antifungal therapy: what comes out of the pipeline in the near future? ^[12]

Prof William Hope^[13], University of Liverpool, United Kingdom*

8. TDM and PK/PD in antifungal therapy: when and why? ^[14]

Prof William Hope^[13], University of Liverpool, United Kingdom*

9. Antimicrobial prophylaxis in HSCT-patients: guidelines and evidence ^[15]

Dr Philipp Wohlfarth^[16], Medical University of Vienna, Austria

10. Hygiene measures, isolation and therapy ^[17]

Prof Dr Annette Schuermans^[18], University Hospitals Leuven, Belgium

11. What's really new in antibiotic therapy ^[19]

Prof Dr Martin J. Hug^[20], Institute of Pharmaceutical Sciences, University of Freiburg, Germany

12. Interactive Part - PKPD & TDM of antifungals ^[21]

Prof Dr Isabel Spriet ^[9], UZ Leuven, Belgium

Prof William Hope ^[13], University of Liverpool, United Kingdom

Last update: 25 September 2019

Links

[1] https://www.eahp.eu/sites/default/files/s1_2.png

[2]

https://www.eahp.eu/sites/default/files/1._therapeutic_drug_monitoring_for_all_drugs_and_for_all_patients.pdf

[3] <http://www.eahp.eu/content/dr-ute-blassmann>

[4]

https://www.eahp.eu/sites/default/files/2._do_we_need_therapeutic_drug_monitoring_for_beta_lactams_or_can_we

[5] https://www.eahp.eu/sites/default/files/3._the_impact_of_pkpd_for_clinical_decisions_0.pdf

[6] <https://www.eahp.eu/content/dr-anouk-muller>

[7]

https://www.eahp.eu/sites/default/files/4._mic_directed_therapy_why_when_and_what_are_the_pitfalls.pdf

[8] https://www.eahp.eu/sites/default/files/5._interactive_part_-_clinical_cases_-_pkpd.pdf

[9] <http://www.eahp.eu/content/prof-dr-isabel-spriet> [10] <http://www.eahp.eu/content/dr-peter-declercq>

[11]

https://www.eahp.eu/sites/default/files/6._implementation_of_check_of_medication_appropriateness_what_can_the

[12]

https://www.eahp.eu/sites/default/files/7._antifungal_therapy_what_comes_out_of_the_pipeline_in_the_near_future

[13] <http://www.eahp.eu/content/prof-william-hope>

[14] https://www.eahp.eu/sites/default/files/8._tdm_and_pkpd_in_antifungal_therapy_when_and_why.pdf

[15]

https://www.eahp.eu/sites/default/files/9._antimicrobial_prophylaxis_in_hsctpatients_guidelines_and_evidence.pdf

[16] <http://www.eahp.eu/content/dr-philipp-wohlfarth>

[17] https://www.eahp.eu/sites/default/files/10._hygiene_measures_isolation_and_therapy.pdf

[18] <http://www.eahp.eu/content/prof-dr-annette-schuermans>

[19] https://www.eahp.eu/sites/default/files/11._whats_really_new_in_antibiotic_therapy_mjh.pdf

[20] <http://www.eahp.eu/content/prof-dr-martin-j-hug-0>

[21] https://www.eahp.eu/sites/default/files/12._interactive_part_-_pkpd_tdm_of_antifungals.pdf